Greg Gumbel's Prostate Cancer Diagnosis

Greg Gumbel, the longtime sports broadcaster for CBS and NBC, was diagnosed with prostate cancer in 1997. He was 51 years old at the time. Gumbel publicly shared his diagnosis and subsequent treatment, making his experience part of a broader conversation about prostate cancer in men, particularly among Black men, who face higher rates of the disease and often receive diagnoses at more advanced stages.

Gumbel underwent surgery to remove his prostate and has remained cancer-free for decades since his treatment. He continued his broadcasting career throughout and after his recovery, working on major sporting events including the Super Bowl and the Olympics. His openness about his diagnosis helped raise awareness about prostate cancer screening and the importance of early detection.

Key Takeaways

  • Greg Gumbel was diagnosed with prostate cancer in 1997 at age 51.
  • He underwent prostate removal surgery as his primary treatment.
  • Gumbel has remained cancer-free for more than 25 years following his treatment.
  • His public disclosure of his diagnosis contributed to broader awareness about prostate cancer screening.
  • Black men face higher prostate cancer rates and are more likely to be diagnosed at advanced stages.

Prostate Cancer: What It Is and Who Gets It

The prostate is a small gland in the male reproductive system that produces fluid for semen. Prostate cancer occurs when malignant cells form in this gland. It is the most common cancer diagnosed in men in the United States, though many men with prostate cancer never experience symptoms or serious complications from it.

Age is the strongest risk factor—prostate cancer is rare before age 40 and becomes more common as men age. Family history also matters: men whose father, brother, or son had prostate cancer face higher risk. Race is another factor. Black men develop prostate cancer at higher rates than white men, are diagnosed at younger ages, and are more likely to have aggressive forms of the disease. Men of Scandinavian descent also face elevated risk.

How Prostate Cancer Is Detected

Prostate cancer is often found through screening tests before symptoms appear. The two main screening methods are the PSA blood test and the digital rectal exam (DRE). The PSA (prostate-specific antigen) test measures a protein produced by the prostate; elevated levels can signal cancer but can also result from benign conditions like infection or enlargement.

If screening results are abnormal, a doctor typically orders an ultrasound-guided biopsy, in which small tissue samples are taken from the prostate and examined under a microscope. A pathologist assigns a Gleason score, which describes how aggressive the cancer cells appear. This score, along with PSA levels and imaging results, helps doctors determine whether the cancer is slow-growing or more serious and what treatment approach makes sense.

Treatment Options for Prostate Cancer

Treatment depends on the cancer's stage, the Gleason score, the patient's age, and overall health. For slow-growing cancers detected early, doctors sometimes recommend active surveillance—regular monitoring with PSA tests and biopsies rather than immediate treatment, since many men die of other causes before prostate cancer becomes life-threatening.

When treatment is needed, surgery to remove the prostate (radical prostatectomy) is one option, as it was for Gumbel. Radiation therapy, either external beam radiation or brachytherapy (radioactive seeds implanted in the prostate), is another. Hormone therapy blocks testosterone, which fuels prostate cancer growth. Chemotherapy is used for advanced cancers. Many men receive a combination of these treatments depending on their specific situation.

Side Effects and Recovery From Prostate Cancer Treatment

Prostate surgery and radiation can cause side effects that vary in severity and duration. Urinary incontinence—leaking urine, especially with physical activity—occurs in some men after surgery, though it often improves over months. Erectile dysfunction is another common effect, since nerves involved in erections run alongside the prostate. Bowel problems like diarrhea or urgency can follow radiation therapy.

Recovery timelines differ by treatment type. After surgery, most men spend one to two days in the hospital and return to light activity within two to three weeks, though full recovery takes longer. Radiation therapy typically involves five days a week of outpatient treatment for several weeks. Many side effects improve or resolve within months to a year, though some persist. Doctors can discuss strategies to manage these effects before treatment begins.

Prostate Cancer Outcomes and Survival Rates

Prostate cancer outcomes have improved significantly over the past few decades. When detected early and confined to the prostate, five-year survival rates exceed 99 percent. Even when cancer has spread to nearby lymph nodes or distant sites, survival rates remain relatively high compared to many other cancers, though outcomes vary based on how far the disease has progressed.

The challenge is that prostate cancer often grows slowly, making it difficult to predict which cancers will become life-threatening and which will remain dormant. This is why screening decisions are individual—a man and his doctor weigh the benefits of early detection against the risks of overtreatment in cancers that would never cause harm. Gumbel's long survival and continued work demonstrate that men treated for prostate cancer can return to active, full lives.

Screening Recommendations and Shared Decision-Making

Major health organizations have different screening recommendations. The American Cancer Society suggests that men have the opportunity to make an informed decision about screening starting at age 50 (or age 40 to 45 for high-risk men, including Black men and those with a family history). The U.S. Preventive Services Task Force recommends shared decision-making conversations between men and doctors about screening for men ages 55 to 69, and suggests against routine screening for men 70 and older.

The key phrase in these recommendations is shared decision-making—a conversation between a man and his doctor about the potential benefits and harms of screening. This approach acknowledges that screening can catch cancer early when treatment is most effective, but can also lead to detection of slow-growing cancers that might never cause problems, resulting in unnecessary treatment and side effects. A man's age, race, family history, and personal values all factor into the decision.

Frequently Asked Questions

Is prostate cancer always fatal?

No. Many men with prostate cancer live for decades without the disease becoming life-threatening. Some slow-growing prostate cancers never cause serious problems. Outcomes depend heavily on how early the cancer is detected and how aggressive it is. Men diagnosed with early-stage prostate cancer have very high survival rates.

Why do Black men have higher prostate cancer rates?

The reasons are not fully understood and likely involve a combination of genetic factors, differences in hormone levels, and health disparities including differences in screening rates and access to care. Black men are also more likely to be diagnosed at advanced stages, which affects outcomes. This is why organizations recommend that Black men discuss prostate cancer screening with their doctor starting at age 40.

Can prostate cancer be prevented?

There is no proven way to prevent prostate cancer, though some research suggests that maintaining a healthy weight, exercising regularly, and eating a diet rich in vegetables may lower risk. Avoiding smoking and limiting alcohol are also recommended for overall health. The most effective strategy remains early detection through screening conversations with a doctor.

What happens if prostate cancer is not treated?

This depends on how aggressive the cancer is. Slow-growing cancers may never cause serious harm, which is why active surveillance is an option for some men. Aggressive cancers that go untreated can spread beyond the prostate to bones, lymph nodes, and other organs, making treatment more difficult and outcomes worse. This is why screening and shared decision-making with a doctor matter.